Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Humana, a major player in the U.S. health insurance market, could be in the crosshairs of Cigna, one of its rivals, according to recent reports.</li><li>Bloomberg has indicated that informal talks between Cigna and Humana have resumed after falling apart last year.</li><li>While the discussions are still in the early stages, the news comes at a time when Humana has been grappling with changes in the government’s Medicare plan ratings, which have impacted its performance.</li></ul>

Humana, a major player in the U.S. health insurance market, could be in the crosshairs of Cigna, one of its rivals, according to recent reports.Bloomberg has indicated that informal talks between Cigna and Humana have resumed after falling apart last year.While the discussions are still in the early stages, the news comes at a time when Humana has been grappling with changes in the government’s Medicare plan ratings, which have impacted its performance.

Humana The Next Major Acquisition Target for Cigna? The Surprising Reasons It Might Go Through!

<ul><li>Humana has presented a mixed set of results for the first quarter of 2024, coupled with adjusted expectations for the upcoming year.</li><li>The company has reaffirmed its full-year adjusted EPS guidance at approximately $16 and increased its membership growth outlook from 100,000 to 150,000 net additions, which speaks to Humana's operational resilience and strategic expansions.</li><li>This performance is supported by inline or positive medical cost trends, and visible growth in their primary care business with a significant upswing in new and mature centers.</li></ul>

Humana has presented a mixed set of results for the first quarter of 2024, coupled with adjusted expectations for the upcoming year.The company has reaffirmed its full-year adjusted EPS guidance at approximately $16 and increased its membership growth outlook from 100,000 to 150,000 net additions, which speaks to Humana's operational resilience and strategic expansions.This performance is supported by inline or positive medical cost trends, and visible growth in their primary care business with a significant upswing in new and mature centers.

Humana Inc.: Enhanced Strategic Management of Benefit Costs and Member Acquisition Tactics! - Major Drivers

<ul><li>Humana Inc., a leading health insurance provider, posted its first quarter results for 2024 and provided some important insights into the company's financial performance and future outlook.</li><li>CEO Bruce Broussard and CFO Susan Diamond shared their insights in a Q&A session following the earnings call.</li><li>Broussard highlighted Humana's solid start to 2024, stating the company reaffirmed its full-year adjusted earnings per share (EPS) guidance at approximately $16 with an increased individual MA membership growth outlook.</li></ul>

Humana Inc., a leading health insurance provider, posted its first quarter results for 2024 and provided some important insights into the company's financial performance and future outlook.CEO Bruce Broussard and CFO Susan Diamond shared their insights in a Q&A session following the earnings call.Broussard highlighted Humana's solid start to 2024, stating the company reaffirmed its full-year adjusted earnings per share (EPS) guidance at approximately $16 with an increased individual MA membership growth outlook.

Humana Inc.: Impacts on Pharmacy Benefit Managers (PBMs) Resulting From IRA Changes & Other Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.</li>
<li>In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.</li>
<li>Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.</li>
</ul>



Asahi Intecc (7747 JP) is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.
In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.
Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.


2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

Junior Finance Analyst, Steno Research

Ulrik Simmelholt

Junior Finance Analyst

Macro and Geopolitical Research House

Steno Research

Steno Research is a new macro and geopolitical research house. We are based out of Copenhagen, Denmark, but have an international team and a strong network of sources and partners around the world. The team is lead by Andreas Steno, previous global head of strategy at Nordea Bank, and Mikkel Rosenvold, former chief consultant in the Danish Ministry of Finance.

Cross Asset Strategy

<ul><li>We’ve received loads of feedback from our clients regarding our Trump versus Biden basket.</li><li>As a result, we will provide a detailed breakdown of both baskets and explain the rationale behind each.</li><li>We are updating the baskets regularly based on the political proposals of the two candidates.</li></ul>

We’ve received loads of feedback from our clients regarding our Trump versus Biden basket.As a result, we will provide a detailed breakdown of both baskets and explain the rationale behind each.We are updating the baskets regularly based on the political proposals of the two candidates.

Equity Watch: The Trump versus Biden Basket

United States

Humana Inc. is a managed health care company with medical members located in the United States and Puerto Rico.  The Company offers coordinated health care through health maintenance organizations, preferred provider organizations, point-of-service plans, and administrative services products.  Humana offers its products to employer groups, government-sponsored plans, and individuals.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Humana Inc (HUM US)

Humana The Next Major Acquisition Target for Cigna? The Surprising Reasons It Might Go Through!

Humana, a major player in the U.S. health insurance market, could be in the crosshairs of Cigna, one of its rivals, according to recent...

Baptista Research

Humana Inc.: Enhanced Strategic Management of Benefit Costs and Member Acquisition Tactics! - Major Drivers

Humana has presented a mixed set of results for the first quarter of 2024, coupled with adjusted expectations for the upcoming year. The company...

Baptista Research

Humana Inc.: Impacts on Pharmacy Benefit Managers (PBMs) Resulting From IRA Changes & Other Major Drivers

Humana Inc., a leading health insurance provider, posted its first quarter results for 2024 and provided some important insights into the...

Baptista Research

2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

Asahi Intecc is poised for double-digit sales growth through FY26, driven by strong market demand for guidewires, market leadership positioning,...

Tina Banerjee

Equity Watch: The Trump versus Biden Basket

We’ve received loads of feedback from our clients regarding our Trump versus Biden basket. As a result, we will provide a detailed breakdown of...

Steno Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)